About Wockhardt Pharma Limited

Wockhardt Limited operates as a worldwide pharmaceutical and biotech organization which maintains operations throughout the UK and Switzerland and Ireland and Russia and multiple additional countries. The company operates manufacturing facilities in India and the UK and Ireland and Dubai while maintaining substantial operations in Europe and India. The Company operates from D-4 M.I.D.C. Chikalthana in Chhatrapati Sambhajinagar Maharashtra 431006 (corporate office: Wockhardt Towers, BKC, Mumbai) where its equity shares are listed on BSE and NSE. The company received its incorporation on July 8th 1999.

Wockhardt dedicates 80% of its operations to pharmaceutical manufacturing and medicinal chemical and botanical product production while conducting 20% of its business through wholesale trading activities. The main business activity of Wockhardt falls under “Manufacture of pharmaceuticals, medicinal and chemical products” which corresponds to NIC 210.

Wockhardt Pharma Geographic Presence

The company operates through 8 Indian plants and 2 offices and 4 international plants and 17 international offices which provide services to 28 Indian states and 47 international countries.

The Group operated through 7 subsidiaries according to Form AOC-1 during March 31 2025.

Wockhardt continues to concentrate on antibiotic research through its development of six new antibiotics which target antibiotic-resistant bacteria. The Company has developed an extensive intellectual property portfolio through its patent filing of 3,273 cumulative applications and its receipt of 848 granted patents as of March 31 2025.

Wockhardt Pharma’s Business Segments

The revenue from operations originated from domestic operations at 22% while international operations generated 78% of total revenue. The company reports its regional distribution as follows:

•       UK 39%
•       European Union 12%
•       US 3%
•       India and Rest of the world 46%.

Wockhardt Pharma’s Key Management

•       Dr. Habil Khorakiwala, Executive Chairman of the company.
•       Dr. Murtaza Khorakiwala, Managing Director and Executive Director.
•       Dr. Huzaifa Khorakiwala, Executive Director at the company.
•       Deepak Madnani, Chief Financial Officer of the company.
•       Rashmi Mamtura, Company Secretary and Compliance Officer of the organization.

Latest Updates(FY25) on Wockhardt Pharma

Approval from Indian Drug Authority: The Indian drug authority approved Miqnaf (Nafithromycin) as a new-generation oral antibiotic for treating Community Acquired Bacterial Pneumonia (CABP). The Company submitted its homegrown fast-acting insulin analog Aspart injection (ASPARAPID) to the Drugs Controller General of India while it develops multiple insulin analogs and GLP-1 agonists.

US FDA Grant: The US FDA granted WCK 6777 Fast Track designation and the US National Institutes of Health conducted a Phase I study that reached successful completion.

Portfolio Expansion: Wockhardt expanded its intellectual property portfolio through the filing of 3,273 cumulative patents and the granting of 848 patents during the period ending March 31 2025.

Product Launch: Wockhardt UK and Ireland launched six new products each throughout the year.

The Company issued Rs 1,000 crore through a Qualified Institutions Placement (QIP) to fund capital expenditures and research and development and growth initiatives and debt reduction.

Entry into vaccine market: Wockhardt established its intention to enter the vaccine market with COVID-19 vaccines and develop integrated drug substance and product manufacturing capabilities.